Business

Azenta, Inc. (AZTA) M&A Call Transcript

Published

on

Azenta, Inc. (AZTA) M&A Call March 10, 2026 10:00 AM EDT

Company Participants

Yvonne Perron – Vice President of Financial Planning & Analysis and Investor Relations
John P. Marotta – President, CEO & Director
Lawrence Lin – Executive VP & CFO

Conference Call Participants

Advertisement

David Saxon – Needham & Company, LLC, Research Division
Paul Knight – KeyBanc Capital Markets Inc., Research Division
Steven Etoch – Stephens Inc., Research Division
Brendan Smith – TD Cowen, Research Division

Presentation

Operator

Advertisement

Hello, and welcome. My name is Jenny, and I will be your conference facilitator today for Azenta’s Acquisition of Uk Biocentre Acquisition Call. [Operator Instructions] As a reminder, this conference call is being recorded today, Tuesday, March 10, 2026.

I will now turn the conference call over to Yvonne Perron, Vice President, FP&A and Investor Relations.

Yvonne Perron
Vice President of Financial Planning & Analysis and Investor Relations

Advertisement

Good morning, everyone, and thank you for joining us. As you know, last week, we announced that Azenta entered into a definitive agreement to acquire Uk Biocentre. The press release and a presentation to accompany today’s call are available on the Investor Relations section of our website. Joining me today are John Marotta, President and Chief Executive Officer; and Lawrence Lin, Chief Financial Officer, who will discuss the strategic rationale for the transaction and provide additional details. Before we begin, I will briefly refer you to the safe harbor statements included in the presentation, which outline important information regarding forward-looking statements and the use of non-GAAP financial measures.

With that, I’ll turn the call over to our CEO, John Marotta.

John P. Marotta
President, CEO & Director

Advertisement

Good morning, everyone, and thank you for joining us today. I’ll use the first portion of our time discussing the strategic rationale behind our acquisition of the Uk Biocentre and how this transaction

Advertisement

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending

Exit mobile version